Mangalam Drugs and Organics Receives NCLT Approval for Merger Scheme
Mangalam Drugs & Organics Limited (MDOL) received an NCLT order admitting a petition for a merger scheme involving Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited. The petition was presented on September 23, 2025, with a final hearing scheduled for December 16, 2025. NCLT has directed notices to be issued to various statutory authorities, giving them 30 days to submit representations. MDOL will keep stock exchanges informed of further developments.

*this image is generated using AI for illustrative purposes only.
Mangalam Drugs & Organics Limited (MDOL) has taken a significant step forward in its corporate restructuring plans. The company recently received a certified true copy of an order from the National Company Law Tribunal (NCLT) Mumbai Bench, admitting a petition for a scheme of merger by absorption.
Key Details of the Merger Scheme
The merger scheme involves the following entities:
- Mangalam Laboratories Private Limited
- Shri JB Pharma Private Limited
- Mangalam Drugs and Organics Limited
NCLT Proceedings
- Petition Presentation Date: September 23, 2025
- Admitting Bench: NCLT Bench-III
- Bench Members:
- Ms. Lakshmi Gurung (Member Judicial)
- Sh. Hariharan Neelakanta Iyer (Member Technical)
- Final Hearing Date: December 16, 2025
Regulatory Notifications
The NCLT has directed notices to be issued to various statutory authorities, including:
- Central Government
- Income Tax Authorities
- Reserve Bank of India
- Securities and Exchange Board of India
- Other relevant regulators
These authorities have been given 30 days to submit their representations regarding the merger scheme.
Next Steps
MDOL has committed to keeping the stock exchanges informed of any further material developments in this matter. The company will need to await the final hearing scheduled for December 16, 2025, where the NCLT will consider the merger scheme for final approval.
Implications for Investors
While the admission of the petition is a positive step towards the company's restructuring plans, investors should note that the final approval is still pending. The outcome of the merger could potentially impact the company's operations, financial structure, and market position.
Mangalam Drugs and Organics Limited continues to demonstrate its commitment to transparency by promptly disclosing this development to the stock exchanges. Investors and stakeholders are advised to keep a close watch on further announcements as the merger process progresses.
Historical Stock Returns for Mangalam Drugs & Organics
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
-1.24% | +0.68% | -8.14% | -12.38% | -42.38% | -51.49% |